HTML Microdata document

This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/chemspider/
foaf	http://xmlns.com/foaf/0.1/
n21	http://linked.opendata.cz/resource/drugbank/company/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/chebi/
n7	http://linked.opendata.cz/resource/mesh/concept/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/wikipedia/
n23	http://bio2rdf.org/drugbank:
n11	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/pharmgkb/
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/pdb/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/kegg-compound/
adms	http://www.w3.org/ns/adms#
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/pubchem-compound/
n14	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/pubchem-substance/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n4	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6	http://linked.opendata.cz/ontology/mesh/
n9	http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00157/identifier/drugbank/
n5	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item: n2:DB00157
rdf:type: n3:Drug
n3:description: NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). It forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed)
n3:generalReferences: # "Link":http://www.wholehealthmd.com/refshelf/substances_view/1,1525,10047,00.html # Belenky P, Bogan KL, Brenner C: NAD+ metabolism in health and disease. Trends Biochem Sci. 2007 Jan;32(1):12-9. Epub 2006 Dec 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17161604 # Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides--small molecules with a multitude of functions. Biochem J. 2007 Mar 1;402(2):205-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17295611 # Khan JA, Forouhar F, Tao X, Tong L: Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007 May;11(5):695-705. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17465726 # Lin SJ, Guarente L: Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol. 2003 Apr;15(2):241-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12648681 # Biellmann JF, Lapinte C, Haid E, Weimann G: Structure of lactate dehydrogenase inhibitor generated from coenzyme. Biochemistry. 1979 Apr 3;18(7):1212-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/218616
n3:group: nutraceutical
n3:indication: Some evidence suggests that NADH might be useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular disease.
owl:sameAs: n14:DB00157 n23:DB00157
dcterms:title: NADH
adms:identifier: n11:PA164755085 n12:Nicotinamide_adenine_dinucleotide n15:C00004 n16:NAI n17:388299 n18:DB00157 n20:439153 n22:46504879 n24:16908
n3:mechanismOfAction: NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
n3:packager: n21:271B4D42-363D-11E5-9242-09173F13E4C5
n3:synonym: nicotinamide adenine dinucleotide (reduced) DPNH 1,4-dihydronicotinamide adenine dinucleotide
n3:toxicity: No reports of overdose, however, high doses of NADH (10 mg a day or more) may cause jitteriness, anxiety, and insomnia.
n3:synthesisReference: Youichi Niimura, Michio Kozaki, Hisashi Yamagata, Miki Ikuta, Yasurou Kurusu, Hideaki Yukawa, Makiko Kukushima, Masato Terasausa, "Process for producing NADH oxidase." U.S. Patent US5416012, issued February, 1984.
n6:hasConcept: n7:M0014404
foaf:page: n9:nad_0179.shtml
n3:IUPAC-Name: n5:271B4D48-363D-11E5-9242-09173F13E4C5
n3:InChI: n5:271B4D4E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n5:271B4D4D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n5:271B4D4A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n5:271B4D4B-363D-11E5-9242-09173F13E4C5
n3:SMILES: n5:271B4D4C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n5:271B4D46-363D-11E5-9242-09173F13E4C5
n3:logP: n5:271B4D47-363D-11E5-9242-09173F13E4C5 n5:271B4D44-363D-11E5-9242-09173F13E4C5 n5:271B4D5F-363D-11E5-9242-09173F13E4C5
n3:logS: n5:271B4D45-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count: n5:271B4D54-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n5:271B4D55-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n5:271B4D4F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n5:271B4D50-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n5:271B4D52-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n5:271B4D51-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n5:271B4D53-363D-11E5-9242-09173F13E4C5
n3:absorption: Unclear how much of an administered dose is absorbed.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 606-68-8
n3:category
n3:containedIn: n4:271B4D43-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n5:271B4D5A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n5:271B4D5C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n5:271B4D5D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n5:271B4D5E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n5:271B4D59-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n5:271B4D58-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n5:271B4D5B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n5:271B4D49-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n5:271B4D56-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n5:271B4D57-363D-11E5-9242-09173F13E4C5